Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Sadick Research Group
2402
mi
from 98109
New York, NY
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Sadick Research Group
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Vital Prospects Clinical Research Institute, P.C.
1565
mi
from 98109
Tulsa, OK
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Vital Prospects Clinical Research Institute, P.C.
1565
mi
from 98109
Tulsa, OK
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DermDox Centers for Dermatology
2303
mi
from 98109
Hazleton, PA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DermDox Centers for Dermatology
2303
mi
from 98109
Hazleton, PA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Clinical Partners, LLC
2482
mi
from 98109
Johnston, RI
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Clinical Partners, LLC
2482
mi
from 98109
Johnston, RI
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Health Concepts
944
mi
from 98109
Rapid City, SD
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Health Concepts
944
mi
from 98109
Rapid City, SD
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Bellaire Dermatology Associates
1889
mi
from 98109
Bellaire, TX
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Bellaire Dermatology Associates
1889
mi
from 98109
Bellaire, TX
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Texas Dermatology and Laser Specialists
1787
mi
from 98109
San Antonio, TX
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Texas Dermatology and Laser Specialists
1787
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Virginia Clinical Research, Inc.
2429
mi
from 98109
Norfolk, VA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Virginia Clinical Research, Inc.
2429
mi
from 98109
Norfolk, VA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
West End Dermatology Associates
2339
mi
from 98109
Richmond, VA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
West End Dermatology Associates
2339
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
TCR Medical Corporation
1065
mi
from 98109
San Diego, CA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
TCR Medical Corporation
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
UPMC Department of Dermatology
2134
mi
from 98109
Pittsburgh, PA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
UPMC Department of Dermatology
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center (UConn Health)
2425
mi
from 98109
Farmington, CT
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center (UConn Health)
2425
mi
from 98109
Farmington, CT
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
MediSearch Clinical Trials
1469
mi
from 98109
Saint Joseph, MO
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
MediSearch Clinical Trials
1469
mi
from 98109
Saint Joseph, MO
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1112
mi
from 98109
Phoenix, AZ
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1112
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
979
mi
from 98109
Los Angeles, CA
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
979
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1031
mi
from 98109
Oceanside, CA
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1031
mi
from 98109
Oceanside, CA
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1503
mi
from 98109
Overland Park, KA
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1503
mi
from 98109
Overland Park, KA
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1938
mi
from 98109
Louisville, KY
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1938
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1359
mi
from 98109
Omaha, NE
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1359
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2159
mi
from 98109
Rochester, NY
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2159
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2206
mi
from 98109
Duncansville, PA
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2206
mi
from 98109
Duncansville, PA
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2481
mi
from 98109
Johnston, RI
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2481
mi
from 98109
Johnston, RI
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1969
mi
from 98109
Nashville, TN
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1969
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2428
mi
from 98109
Norfolk, VA
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2428
mi
from 98109
Norfolk, VA
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
440
mi
from 98109
Calgary,
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
440
mi
from 98109
Calgary,
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Pinnacle Research Group, LLC
2121
mi
from 98109
Anniston, AL
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Pinnacle Research Group, LLC
2121
mi
from 98109
Anniston, AL
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Alliance Dermatology & MOHS Center, PC
1106
mi
from 98109
Phoenix, AZ
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Alliance Dermatology & MOHS Center, PC
1106
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Southern California Dermatology, Inc.
987
mi
from 98109
Santa Ana, CA
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Southern California Dermatology, Inc.
987
mi
from 98109
Santa Ana, CA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
2526
mi
from 98109
DeLand, FL
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
2526
mi
from 98109
DeLand, FL
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Jacksonville Center for Clinical Research
2456
mi
from 98109
Jacksonville, FL
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Jacksonville Center for Clinical Research
2456
mi
from 98109
Jacksonville, FL
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Renstar Medical Research
2483
mi
from 98109
Ocala, FL
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Renstar Medical Research
2483
mi
from 98109
Ocala, FL
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research
405
mi
from 98109
Boise, ID
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research
405
mi
from 98109
Boise, ID
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
1440
mi
from 98109
Wichita, KA
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
1440
mi
from 98109
Wichita, KA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
2206
mi
from 98109
Duncansville, PA
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
2206
mi
from 98109
Duncansville, PA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Menter Dermatology Research Institute
1681
mi
from 98109
Dallas, TX
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Menter Dermatology Research Institute
1681
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
New Horizon Research Center
2732
mi
from 98109
Miami, FL
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
New Horizon Research Center
2732
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Medical Research South
2419
mi
from 98109
Charleston, SC
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Medical Research South
2419
mi
from 98109
Charleston, SC
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Dorothea
mi
from 98109
Chomutov,
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Dorothea
mi
from 98109
Chomutov,
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Clinical Research Atlanta
2194
mi
from 98109
Stockbridge, GA
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Clinical Research Atlanta
2194
mi
from 98109
Stockbridge, GA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
1523
mi
from 98109
Oklahoma City, OK
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
1523
mi
from 98109
Oklahoma City, OK
Click here to add this to my saved trials
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated:  12/31/1969
Dawes Fretzin Clinical Research
1870
mi
from 98109
Indianapolis, IN
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated: 12/31/1969
Dawes Fretzin Clinical Research
1870
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated:  12/31/1969
PAREXEL-Phase 1 Baltimore Harbor Hospital Center
2330
mi
from 98109
Baltimore, MD
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated: 12/31/1969
PAREXEL-Phase 1 Baltimore Harbor Hospital Center
2330
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
2206
mi
from 98109
Duncansville, PA
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
2206
mi
from 98109
Duncansville, PA
Click here to add this to my saved trials
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated:  12/31/1969
Parexel Early Phase Unit at Glendale
955
mi
from 98109
Glendale, CA
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated: 12/31/1969
Parexel Early Phase Unit at Glendale
955
mi
from 98109
Glendale, CA
Click here to add this to my saved trials
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Lycera Investigational Site
2391
mi
from 98109
East Windsor, NJ
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Lycera Investigational Site
2391
mi
from 98109
East Windsor, NJ
Click here to add this to my saved trials
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Lycera Investigational Site
1863
mi
from 98109
Carmel, IN
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Lycera Investigational Site
1863
mi
from 98109
Carmel, IN
Click here to add this to my saved trials
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Lycera Investigational Site
2472
mi
from 98109
Andover, MA
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Lycera Investigational Site
2472
mi
from 98109
Andover, MA
Click here to add this to my saved trials
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Lycera Investigational Site
1389
mi
from 98109
Fridley, MN
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Lycera Investigational Site
1389
mi
from 98109
Fridley, MN
Click here to add this to my saved trials
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Lycera Investigational Site
2183
mi
from 98109
High Point, NC
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Lycera Investigational Site
2183
mi
from 98109
High Point, NC
Click here to add this to my saved trials